yahoo_financeOriginal article
AbCellera’s ABCL-635 Cuts Menopause Hot Flashes 83% in Phase II Trial
Phase 2positiveABCL-635Positive
AI Analysis
Summary
AbCellera reported positive Phase 2 trial results for ABCL-635, demonstrating an 83% reduction in menopause hot flashes. The data supports further development of the candidate for this indication.
Clinical Trial Data
Phase
2
Primary Endpoint
Met
Outcome Details
83% reduction in menopause hot flashes
Importance:6/10
Sentiment:
0.75
Phase 2menopausehot flashespositive dataclinical trial
Related Companies
Read the original article
Published by yahoo_finance on August 10, 2026 1:03 PM